Condition

Diffuse Cutaneous Systemic Sclerosis clinical trials and research

• 7Clinical trials
• 14Countries

Newest Diffuse Cutaneous Systemic Sclerosis clinical trials

All recruiting trials (7)

• Using long-lived immune cells to calm an overactive immune system

  This trial will try QEL-005, an autologous CD19-directed CAR-T regulatory cell therapy, to calm immune overactivity in adults with diffuse cutaneous systemic sclerosis or difficult-to-treat rheumatoid arthritis.

  Recruiting at 7 sites Phase 1/2 Quell Therapeutics Limited · Düsseldorf and 9 other locations · NCT07473154

• MTX-474 for diffuse cutaneous systemic sclerosis (dcSSc)

  This trial will test whether IV MTX-474 given every four weeks helps people with diffuse cutaneous systemic sclerosis compared with placebo.

  Recruiting at 20 sites Phase 2 Mediar Therapeutics · Phoenix, Arizona and 57 other locations · NCT07287670

• Evaluating Baricitinib for Skin Tightening in Systemic Sclerosis

  This study is testing if a new medication called baricitinib can help improve skin tightness in people with diffuse cutaneous systemic sclerosis compared to a standard treatment.

  Recruiting Phase 3 Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh · Dhaka · NCT06936215

• Evaluating CTX112 for treating refractory autoimmune diseases in adults

  This study is testing a new CAR T cell treatment called CTX112 to see if it can help adults with tough autoimmune diseases like lupus and scleroderma feel better.

  Recruiting at 16 sites Phase 1 CRISPR Therapeutics · La Jolla, California and 16 other locations · NCT06925542

• Zamtocabtagene Autologous CAR-T for Autoimmune Diseases

  This early-phase study tests whether a patient’s own CAR-T cells (zamto-cel) can be safely given after standard therapy to people with lupus or systemic sclerosis.

  Recruiting Phase 1 Miltenyi Biomedicine GmbH · Milwaukee, Wisconsin · NCT06708845

• Testing Telitacicept for treating systemic sclerosis

  This study is testing if Telitacicept can help adults with early diffuse cutaneous systemic sclerosis feel better when used alongside another medication called Mycophenolate Mofetil.

  Recruiting at 9 sites Phase 2 Second Affiliated Hospital, Zhejiang University, School of Medicine · Yangzhou, Jiangsu and 8 other locations · NCT06375005

• Extracorporeal Photopheresis for Early Diffuse Cutaneous Systemic Sclerosis

  This study tests whether extracorporeal photopheresis can help people with early diffuse cutaneous systemic sclerosis see if it’s safe and might improve skin symptoms.

  Recruiting Phase 2 London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · London, Ontario · NCT04986605

Related topics

Quick answers

How many Diffuse Cutaneous Systemic Sclerosis clinical trials are recruiting right now?

7, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 14 countries. The most sites are in Spain (3 trials), United States (3 trials), United Kingdom (2 trials), Germany (2 trials), Australia (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 3, Phase 1: 2, Phase 3: 1, Phase 1/2: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →